Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes.
Autologous cytotoxic T lymphocytes (CTL) against primary-cultured malignant gliomas were generated from peripheral blood mononuclear cells in vitro in 4 patients. Activities of the CTL were highly specific to the corresponding autologous glioma and were inhibited, in one patient, with antibodies against CD3, CD8 and MHC-class I molecules. When the CTL were injected 3 times into the primary-tumor-resected cavity via an Ommaya tube, reduction of the recurrent tumors with magnetic resonance imaging (MRI)-measured volumes exceeding 45 cm3 was observed in 3 patients. In a patient with glioblastoma multiforme (GBM), the tumor volume (estimated, 130 cm3) was rapidly reduced to 1/3, although re-recurrence of the tumor followed 40 days later. A slight but distinct rapid reduction of the tumor volume was observed in another GBM patient and in an anaplastic astrocytoma patient; essentially no change was observed in a further GBM patient. These results suggest that adoptive immunotherapy with autologous CTL will be clinically effective against end-stage malignant gliomas.
Tsurushima
H
H
Department of Neurosurgery, Institute of Clinical Medicine, University of Tsukuba, Tsukuba Science City, Ibaraki.
Liu
S Q
SQ
Tuboi
K
K
Matsumura
A
A
Yoshii
Y
Y
Nose
T
T
Saijo
K
K
Ohno
T
T
D000328:Adult; D015703:Antigens, CD / Q000097:blood; D000954:Antigens, Surface / Q000097:blood; D018450:Disease Progression; D005260:Female; D005909:Glioblastoma / Q000473:pathology / Q000628:therapy*; D006801:Humans; D016130:Immunophenotyping; D016219:Immunotherapy, Adoptive; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D013602:T-Lymphocytes, Cytotoxic / Q000637:transplantation*; D014182:Transplantation, Autologous
D015703:Antigens, CD; D000954:Antigens, Surface